5-[[2-[(2-benzyl-3-tert-butylsulfonylpropanoyl)amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-N-butyl-6-cyclohexyl-4-hydroxy-2-propan-2-ylhexanamide | 114469-22-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 5-[[2-[(2-benzyl-3-tert-butylsulfonylpropanoyl)amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-N-butyl-6-cyclohexyl-4-hydroxy-2-propan-2-ylhexanamide
• CAS: 114469-22-6
• 化学式: C₃₉H₆₃N₅O₆S
• 分子量: 730.0
• InChiKey: GGKXIITZBSPCQP-UHFFFAOYSA-N

物化性质

• 熔点：
  148-149 °C(Solv: dichloromethane (75-09-2); hexane (110-54-3))
• 沸点：
  1019.7±65.0 °C(Predicted)
• 密度：
  1.142±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  51
• 可旋转键数：
  21
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  179
• 氢给体数：
  5
• 氢受体数：
  7

文献信息

• Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor
  申请人：SCHERING CORPORATION

  公开号：EP0498361A2

  公开（公告）日：1992-08-12

  Treatment of hypertension or congestive heart failure with a combination of an angiotensin II antagonist or a renin inhibitor with a neutral endopeptidase inhibitor, pharmaceutical compositions comprising said combinations and kits for administering separate pharmaceutical compositions in combination are disclosed, wherein the angiotensin II antagonists include saralasin, sar 1, ile 8 angiotensin II, Dup 753, EXP 6155, EXP 6803 and PD 123319, the renin inhibitors include enalkrein, RO 42-5892, A 65317, CP 80794, ES 1005, ES 8891, SQ 34017, CGP 29287, CGP 38560, SR 43845, U-71038, A 62198, and A 64662, and the neutral endopeptidase inhibitors include N-[N-[1(S)-carboxyl-3-phenylpropyl]-(S)-phenylalanyl]-(S)-isoserine, N-[N-[((1S)-carboxy-2-phenyl)ethyl]-(S)-phenylalanyl]-β-alanine; N-[2(S)-mercaptomethyl-3-(2-methylphenyl)-propionyl]methionine, SQ 28603, UK 69578, SQ 29072, thiorphan, retro-thiorphan and phosphoramidon.

  本发明公开了用血管紧张素II拮抗剂或肾素抑制剂与中性内肽酶抑制剂的组合物治疗高血压或充血性心力衰竭的方法、包含所述组合物的药物组合物以及用于联合施用单独药物组合物的试剂盒，其中血管紧张素II拮抗剂包括saralasin、sar 1、ile 8 angiotensin II、Dup 753、EXP 6155、EXP 6803和PD 123319，肾素抑制剂包括enalkrein、RO 42-5892、A 65317、CP 80794和PD 123319、Dup 753、EXP 6155、EXP 6803 和 PD 123319，肾素抑制剂包括 enalkrein、RO 42-5892、A 65317、CP 80794、ES 1005、ES 8891、SQ 34017、CGP 29287、CGP 38560、SR 43845、U-71038、A 62198、和 A 64662，中性内肽酶抑制剂包括 N-[N-[1(S)-羧基-3-苯基丙基]-(S)-苯丙氨酰]-(S)-异丝氨酸、N-[N-[((1S)-羧基-2-苯基)乙基]-(S)-苯丙氨酰]-β-丙氨酸；N-[2(S)-巯甲基-3-(2-甲基苯基)-丙酰基]蛋氨酸、SQ 28603、UK 69578、SQ 29072、thiorphan、retro-thiorphan 和 phosphoramidon。
• [EN] COMBINATION OF AN ANGIOTENSIN II ANTAGONIST OR RENIN INHIBITOR WITH A NEUTRAL ENDOPEPTIDASE INHIBITOR
  申请人：——

  公开号：WO1992013564A1

  公开（公告）日：1992-08-20

  [FR] L'invention concerne le traitement de l'hypertension ou de l'insuffisance cardiaque congestive à l'aide d'une combinaison d'un antagoniste d'angiotensine II ou d'un inhibiteur de rénine avec un inhibiteur d'endopeptidase neutre, des compositions pharmaceutiques comprenant lesdites combinaisons ainsi que des matériels d'administration de compositions pharmaceutiques séparées en combinaison, dans lesquelles les antagonistes de l'angiotensine II comprennent la saralasine, sar 1, ile 8 angiotensine II, Dup 753, EXP 6155, EXP 6803 et PD 123319, les inhibiteurs de rénine comprennent l'enalkreine, RO 42-5892, A 65317, CP 80794, ES 1005, ES 8891, SQ 34017, CGP 29287, CGP 38560, SR 43845, U-71038, A 62198, et A 64662, et les inhibiteurs d'endopeptidase neutre comprennent N-[N-[1(S)-carboxylé-3-phénylpropylé]-(S)-phénylalanylé]-(S)-isosérine, N-[N-[((1S)-carboxy-2-phénylé)éthylé]-(S)-phénylalanylé]-beta-alanine; N-[2(S)-mercaptométhylé-3-(2-méthylphénylé)-propionyl]méthionine, SQ 28603, UK 69578, SQ 29072, thiorphane, rétro-thiorphane et phosphoramidon.
  [EN] Treatment of hypertension or congestive heart failure with a combination of an angiotensin II antagonist or a renin inhibitor with a neutral endopeptidase inhibitor, pharmaceutical compositions comprising said combinations and kits for administering separate pharmaceutical compositions in combination are disclosed, wherein the angiotensin II antagonists include saralasin, sar 1, ile 8 angiotensin II, Dup 753, EXP 6155, EXP 6803 and PD 123319, the renin inhibitors include enalkrein, RO 42-5892, A 65317, CP 80794, ES 1005, ES 8891, SQ 34017, CGP 29287, CGP 38560, SR 43845, U-71038, A 62198, and A 64662, and the neutral endopeptidase inhibitors include N-[N-[1(S)-carboxyl-3-phenylpropyl]-(S)-phenylalanyl]-(S)-isoserine, N-[N-[((1S)-carboxy-2-phenyl)ethyl]-(S)-phenylalanyl]-$g(b)-alanine; N-[2(S)-mercaptomethyl-3-(2-methylphenyl)-propionyl]methionine, SQ 28603, UK 69578, SQ 29072, thiorphan, retro-thiorphan and phosphoramidon.